PeptidePedia The community reference

Talk:Growth hormone secretagogue

Discussion page·2 threads·no archives

This article is within the scope of the pharmacology working group.

This is the discussion page for the article Growth hormone secretagogue. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Feedback as the limiting factorResolved

Intact feedback is both the safety argument for secretagogues and the reason their effect is bounded. Stating both halves is necessary. — SecretagogueSol (talk) 09:45, 12 March 2026 (UTC)

And it is a mechanistic statement rather than a claim about any product. ✓ Done — IpamorelinIsold (talk) 13:20, 12 March 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Thin evidence baseDone

Naming what is thin — small studies, short durations, surrogate endpoints — is better than saying evidence is limited. — PrimarySrcPatia (talk) 10:15, 2 June 2026 (UTC)

Agreed, and it distinguishes the approved compound from the rest without editorialising. ✓ Done — HedgeHedda (talk) 13:50, 2 June 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 2 June 2026, by HedgeHedda. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).